Pharmacogenomic insights into treatment and management of statin-induced myopathy

被引：13

作者：

Peters, Bas J. M. ^{[1
]}

Klungel, Olaf H. ^{[1
]}

Visseren, Frank L. ^{[2
]}

de Boer, Anthonius ^{[1
]}

Maitland-van der Zee, Anke-Hilse ^{[1
]}

机构：

[1] Univ Utrecht, UIPS, Dept Pharmacoepidemiol & Pharmacotherapy, NL-3508 TB Utrecht, Netherlands

[2] Univ Med Ctr Utrecht, Dept Vasc Med, NL-3508 GA Utrecht, Netherlands

来源：

GENOME MEDICINE | 2009年 / 1卷

关键词：

SLCO1B1; POLYMORPHISM; PHARMACOKINETICS; SIMVASTATIN; PATIENT; RHABDOMYOLYSIS; PRAVASTATIN; VARIANTS; THERAPY; SAFETY; ABCB1;

D O I：

10.1186/gm120

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Although statins are generally well tolerated, the most common adverse drug reaction from statin therapy is myopathy. This article reviews the current pharmacogenomic knowledge of statin-induced myopathy. Furthermore, we will discuss the importance of recent pharmacogenetic advances for the treatment and management of statin-induced myopathy. Variation in the SLCO1B1 gene is associated with increased incidence of statin-induced myopathy, particularly with simvastatin and less so with other statins. If different pharmacokinetic enzymes and transporters are responsible for susceptibility to myopathy, this may explain differences in the occurrence of statin-induced myopathy in individual patients. Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin for the lowest chance of developing myopathy.

引用

页数：4

共 27 条

[1]

[Anonymous], AM J CARDIOL, DOI DOI 10.1016/J.AMJCARD.2005.12.010

[2] Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study [J].

Bruckert, E ;

Hayem, G ;

Dejager, S ;

Yau, C ;

Bégaud, B .

CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (06) :403-414

[3] The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment [J].

Fiegenbaum, M ;

da Silveira, FR ;

Van der Sand, CR ;

Van der Sand, LC ;

Ferreira, MEW ;

Pires, RC ;

Hutz, MH .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (05) :551-558

[4] CYP2D6*4 polymorphism is associated with statin-induced muscle effects [J].

Frudakis, Tony N. ;

Thomas, Matthew J. ;

Ginjupalli, Siva N. ;

Handelin, Barbara ;

Gabriel, Richard ;

Gomez, Hector J. .

PHARMACOGENETICS AND GENOMICS, 2007, 17 (09) :695-707

[5] Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy [J].

Furihata, Tomomi ;

Satoh, Naoki ;

Ohishi, Tomoharu ;

Ugajin, Miyuki ;

Kameyama, Yoshio ;

Morimoto, Kaori ;

Matsumoto, Sayaka ;

Yamashita, Keiko ;

Kobayashi, Kaoru ;

Chiba, Kan .

PHARMACOGENOMICS JOURNAL, 2009, 9 (03) :185-193

[6] Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs [J].

Graham, DJ ;

Staffa, JA ;

Shatin, D ;

Andrade, SE ;

Schech, SD ;

La Grenade, L ;

Gurwitz, JH ;

Chan, KA ;

Goodman, MJ ;

Platt, R .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (21) :2585-2590

[7] Treatment of McArdle disease [J].

Haller, RG .

ARCHIVES OF NEUROLOGY, 2000, 57 (07) :923-924

[8] A comprehensive review of genetic association studies [J].

Hirschhorn, JN ;

Lohmueller, K ;

Byrne, E ;

Hirschhorn, K .

GENETICS IN MEDICINE, 2002, 4 (02) :45-61

[9] A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin [J].

Ishikawa, C ;

Ozaki, H ;

Nakajima, T ;

Ishii, T ;

Kanai, S ;

Anjo, S ;

Shirai, K ;

Inoue, I .

JOURNAL OF HUMAN GENETICS, 2004, 49 (10) :582-585

[10] Narrative Review: Statin-Related Myopathy [J].

Joy, Tisha R. ;

Hegele, Robert A. .

ANNALS OF INTERNAL MEDICINE, 2009, 150 (12) :858-U63

← 1 2 3 →